The group's principal activity is to develop pharmaceutical products based on innovative proprietary oral drug delivery technologies. The group's technology platform is based on timerx, an extended release delivery system that is adaptable to soluble and insoluble drugs, and that is flexible for a variety of controlled released profiles. It has also developed two additional oral drug delivery systems, geminex and syncrodose. Geminex is a drug delivery system that is designed to provide independent release of different active ingredients contained in a drug. Syncrodose is a drug delivery system that is designed to release the active ingredient of a drug at the desired site and time in the digestive tract. On 27-Feb-2003 the group sold its excipient business to subsidiaries and affiliates of josef rettenmaier holding gmbh & co kg.
